Emambux Sheik, Italiano Antoine
a Early Phase Trials and Sarcoma Units , Institut Bergonié , Bordeaux , France.
Expert Opin Pharmacother. 2017 Jun;18(8):819-824. doi: 10.1080/14656566.2017.1326908.
Metastatic soft tissue sarcoma, a devastating disease, has a median overall survival of only 12-18 months. Treatment options remain scarce. However, eribulin mesylate, a first-in-class halichondrin B-based microtubule dynamics inhibitor, has recently been approved for the management of patients with advanced liposarcoma. Areas covered: Based on a review of the literature between 2005 and 2017, we present a summary of eribulin mesylate's mechanism of action and the studies showing its clinical efficacy in locally advanced or metastatic sarcomas. Expert commentary: Future development includes the definition of a biomarker signature related to patient outcome with eribulin. Further investigation via controlled clinical trials is needed to identify combination regimens that can optimize the efficacy of eribulin while providing an acceptable safety profile in sarcoma patients.
转移性软组织肉瘤是一种毁灭性疾病，其总生存期的中位数仅为12 - 18个月。治疗选择仍然有限。然而，甲磺酸艾瑞布林是首个基于海兔毒素B的微管动力学抑制剂，最近已被批准用于治疗晚期脂肪肉瘤患者。涵盖领域：基于对2005年至2017年文献的综述，我们总结了甲磺酸艾瑞布林的作用机制以及显示其在局部晚期或转移性肉瘤中临床疗效的研究。专家评论：未来的发展包括确定与甲磺酸艾瑞布林治疗患者预后相关的生物标志物特征。需要通过对照临床试验进行进一步研究，以确定能够优化艾瑞布林疗效同时在肉瘤患者中提供可接受安全性的联合治疗方案。
